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Abstract
Background: To determine the serum levels of the lectin pathway proteins early in the disease course and 17 years
after disease onset and to correlate the protein levels to markers of disease activity in participants from a population-
based Nordic juvenile idiopathic arthritis (JIA) cohort. Additionally, to assess the predictive value of lectin pathway
proteins with respect to remission status.
Methods: A population-based cohort study of consecutive cases of JIA with a disease onset from 1997 to 2000 from
defined geographical areas of Finland, Sweden, Norway and Denmark with 17 years of follow-up was performed.
Clinical characteristics were registered and H-ficolin, M-ficolin, MASP-1, MASP-3, MBL and CL-K1 levels in serum were
analyzed.
Results: In total, 293 patients with JIA were included (mean age 23.7 ± 4.4 years; mean follow-up 17.2 ± 1.7 years).
Concentrations of the lectin protein levels in serum were higher at baseline compared to the levels 17 years after
disease onset (p≤ 0.006, n = 164). At baseline, the highest level of M-ficolin was observed in systemic JIA. Further, high
M-ficolin levels at baseline and at 17-year follow-up were correlated to high levels of ESR. In contrast, high MASP-1 and
MASP-3 tended to correlate to low ESR. CL-K1 showed a negative correlation to JADAS71 at baseline.
None of the protein levels had prognostic abilities for remission status 17 years after disease onset.
Conclusion: We hypothesize that increased serum M-ficolin levels are associated with higher disease activity in JIA and
further, the results indicate that MASP-1, MASP-3 and CL-K1 are markers of inflammation.
Keywords: JIA, Lectin pathway proteins, Disease activity
Background
Juvenile idiopathic arthritis (JIA), which is the most
common rheumatic disease in childhood [1, 2], is a het-
erogeneous disease. The pathophysiology and etiology
are multi-factorial and not fully understood. There is an
increasing body of evidence that inadequately controlled
activation of complement factors leading to either over-
activity or deficiency may be involved in the
pathogenesis of some autoimmune diseases [3–6]. How-
ever, the role of the complement system in JIA is still
not fully elucidated [7–11]. Most studies involve investi-
gations of the classical and the alternative pathway and
have shown contradictory results [7, 9, 12–14]. The third
initiating pathway of the complement system is the lec-
tin pathway. This pathway is triggered by binding of one
or more of the two collectin molecules mannose-binding
lectin (MBL) and Collectin-LK (a heterodimer of the
two polypeptide chains, Collectin-Liver 1 and Collectin-
Kidney 1), or the ficolins (H-ficolin, L-ficolin and M-
ficolin) to glycosylated surfaces on microbial cell walls
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or altered-self cells, normally confined to the immune
system. Upon the binding to adequate patterns enzym-
atic proteins called MBL-associated serine proteases
(MASPs) become activated [15–17]. Autoactivation of
MASP-1 is followed by cleavage of MASP-2. The active
protease of MASP-2 cleaves C4 and C2 forming a C4b2a
convertase that subsequently cleaves C3. Consequently,
activation of the common pathway eliminates target
structures by initiation of membrane-attack complexes
and inflammatory reactions. Active forms of MASP-3
activates Factor D which is a key enzyme of the alterna-
tive pathway in the complement system [18].
The relationship between the lectin dependent path-
way and JIA is poorly understood.
Genetically determined deficiencies in some JIA cat-
egories have been investigated, and MBL polymorphisms
are the most investigated variant alleles as they have
been suggested to be associated with erosions and early
onset of rheumatoid arthritis [19–21]. However, in JIA
the results regarding MBL alleles have been contradict-
ory. Gergely and colleagues [22] found that the MBL
levels were lower in JIA than in controls and that there
was an association between MBL gene mutations and
predisposition to JIA, which is in contrast with the find-
ings of Kang et al. [23].
Studies on the remaining lectin pathway proteins in
JIA are scarce [11, 24]. In 2015, Petri et al. [24] com-
pared the lectin pathway protein levels in patients with
oligoarticular and systemic JIA (sJIA). They found that
plasma levels of M-ficolin and MASP-2 were signifi-
cantly higher in the sJIA group, which correlated posi-
tively to the levels of C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR)). Additionally, M-
ficolin levels correlated positively to the number of ac-
tive joints. In JIA patients, Kasperkiewicz et al. [11]
found no differences in the levels of M-ficolin or MASP-
2 compared to controls but L-ficolin levels were lower in
the oligoarticular JIA group. However, this was not re-
lated to clinical parameters.
Since the clinical implications of the lectin pathway
proteins in JIA have previously been studied in very se-
lected cohorts, we aimed to ponder the role of the lectin
pathway in the non-selected, close to population-based
Nordic JIA cohort. Specifically, our targets were to in-
vestigate the serum levels of lectin pathway proteins
early in the disease course and 17 years after disease on-
set, to correlate with markers of disease activity and to
explore the predictive capacity of the proteins with re-
spect to achievement of remission.
Materials and methods
Study design
We performed a multicenter-based, prospective, observa-
tional study of participants from the close to population-
based Nordic JIA cohort 17 years after disease onset.
We included consecutive cases of newly diagnosed
JIA patients from defined geographical areas of
Denmark, Finland, Norway and Sweden, as previously
described in detail [25]. Inclusion time was in the
early biologic era from January 1st, 1997 to June
30th, 2000. A baseline visit was aimed to take place 6
months (− 1/+ 2 months) after disease onset and pro-
spectively follow-up thereafter [1, 26]. In the original
cohort, 510 JIA patients were included; however, one
center had no access to storage of blood samples at
baseline and accordingly, this center was not included
in comparison of baseline and 17-year data (Fig. 1).
All eligible patients were invited to participate irre-
spectively of disease activity, level of treatment and
disease course to ensure a non-selected setting. The
17-year follow-up visit included updating of the
demographic data, a clinical examination and blood
samples. We applied the juvenile arthritis disease ac-
tivity score for 71 joints (JADAS71) [27] and the ACR
2011 criteria for disease inactivity and remission [28].
Fig. 1 Flow chart of the study population. F = female, M =male,
JIA = juvenile idiopathic arthritis. *The Finnish part of the cohort (n =
151) did not have any baseline samples taken
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Inclusion criteria
Patients fulfilling the ILAR criteria [29] for JIA and hav-
ing at least a baseline and a 17-year follow-up visit.
There were no exclusion criteria.
Protein assays
We measured H-ficolin, M-ficolin, MASP-1, MASP-3,
MBL and collectin-K1 in serum at baseline and after 17
years. Because of limited serum volumes available, CL-
L1, MASP-2 and MAp19 were not measured. L-ficolin
was not measured as plasma samples are needed for test
of this protein.
All samples were collected in serum tubes, centrifuged,
aliquoted and stored at − 80 °C. Previously, lectins have
been proven stable to repeated freeze/thaw cycles [30] and
the baseline samples were thawed no more than two times.
All concentrations were measured by validated in-house
time-resolved immunofluorometric assay (TRIFMA) using
a primary coat consisting of the relevant monoclonal anti-
body as previously described [30–35]. The principles of
TRIFMA are similar to those of the enzyme-linked im-
munosorbent assay (ELISA) apart from the utilization of
long-lasting fluorescence of europium as the labeling probe
for the readout. To sum up, for the six proteins, diluted
samples were incubated in microtiter wells coated with the
relevant antibodies, binding the protein of interest to the
antibody, and subsequently incubated with biotinylated
antibodies and finally with europium-labeled streptavidin.
The signal from the europium caught in the wells was read
as time-resolved fluorometry. To ensure reproducibility
three quality controls were added to each plate, and only
when these values were below 15% variability the results of
the plate were accepted.
Ethics
This study was approved by the national research com-
mittees (1–10–72-280-13, 2012/2051, Dnr 2014/413–31,
174/13/03/03/2014), and all patients gave their written
informed consent. Additionally, Institutional Review
Board approval was granted.
Statistical analysis
Descriptive statistics of mean and standard deviation
(SD) or median and interquartile range (IQR) was used
to assess the clinical characteristics of the cohort.
The concentrations of the six proteins were non-nor-
mally distributed, as evaluated by qq-plot and histogram.
A χ2 test was used for comparison of dichotomous vari-
ables. The Mann–Whitney U test, Kruskal-Wallis test
and Spearman’s rank correlation were used in the com-
parison of ordinal data. The Spearman’s rank correlation
(rho) was defined as a strong correlation if ρ > 0.5,
medium if 0.3 < ρ < 0.5 and weak if 0.1 < ρ < 0.3. Univari-
ate and multivariate regression analyses were performed
to assess the protein levels as baseline predictors of devel-
opment of remission off medication or inactive disease 17
years after disease onset. The level of significance (p) was
defined as ≤0.05.
Results
Study population
Of 510 eligible patients with a JIA onset from 1997 to
2000, blood samples were available in 238/510 at base-
line. In 293/329 participants attending a clinical visit 17
years after disease onset blood samples were accessible.
Among these 293 participants, additional blood samples
from baseline were available in 164 participants (Fig. 1).
The mean follow-up period was 17.2 ± 1.7 years (mean ±
SD) after onset and the mean age of the study partici-
pants was 23.7 ± 4.4 years (mean ± SD) with 71% being
females (Table 1). At baseline, ESR was significantly
higher among participants with sJIA compared to the
other JIA categories (median 27 mm/h and 14mm/h, re-
spectively; p = 0.03). Disease-modifying anti-rheumatic
drugs (DMARDs) were prescribed in 45/238 (18.9%)
cases at baseline. The distribution of JIA categories is
described in Table 1. In general, the disease activity was
low at the 17-year follow-up visit with a median active
Table 1 Clinical characteristics of participants in the Nordic JIA
cohort at the 17-year follow-up visit
Total cohort
N = 293
Females, n (%) 208 (71.0)
Age at onset, y* 6.5 ± 4.1
Age at follow-up, y* 23.7 ± 4.4
Disease duration, y* 17.2 ± 1.7
ANA positive, n (%) 89 (30.4)
HLA-B27 positive, n (%) 66 (22.5)
CRP > 10 mg/L, n (%) 16 (5.4)
ESR > 20 mm/h, n (%) 18 (6.1)
Active joint count, median (IQR) 0 (0–0)
Cumulative joints, median (IQR) 8(4–15)
JADAS71≤ 1, n (%) 126 (43.0)
Systemic JIA 13 (4.4%)
Oligoarticular persistent 66 (22.5%)
Oligoarticular extended 55 (18.8%)
Polyarticular RF negative 53 (18.1%)
Polyarticular RF positive 5 (1.7%)
Psoriatic 19 (6.5%)
Enthesitis-related arthritis 33 (11.3%)
Undifferentiated 49 (16.7%)
y* mean in years ±SD, ANA antinuclear antibodies, HLA-B27 human leucocyte
antigen B27, CRP C-Reactive Protein, ESR Erythrocyte Sedimentation Rate, IQR
1st-3rd interquartile range, JADAS71 juvenile arthritis disease activity score of
71 joints, RF rheumatoid factor
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joint count of 0 (IQR 0–0) and 43% were clinically in-
active with a JADAS71 ≤ 1. For further clinical character-
istics at baseline and 17 years of follow-up, see
Additional file 1: Table S1 and Additional file 2:
Table S2. There was no significant difference in the
age at onset or the distribution of JIA categories
among the 293 participants with available blood sam-
ples at the 17-year follow-up compared to the 217
with no available blood samples. However, signifi-
cantly more girls (p < 0.01) and a higher number of
active joints at the baseline visit were found in the in-
cluded group (p < 0.001).
Levels of the lectin pathway proteins at baseline and 17-
year follow-up
We measured H-ficolin, M-ficolin, MASP-1, MASP-3,
MBL and collectin-K1 levels in serum at baseline and at
the 17-year follow-up and the results are shown in
Table 2.
Comparing the protein levels at baseline to the 17-year
values showed significantly higher baseline levels for all
proteins (Fig. 2, Wilcoxon, Z = -3.255 - -7.812, p = 0.006
or less). The reduction of serum levels was in the range
of 12.5–30%, most pronounced for M-ficolin.
Correlation between gender, JIA categories and lectin
pathway levels
No gender difference in protein levels was found at base-
line (p = 0.11–0.92).
At baseline highest levels of M-ficolin were found in
the systemic group (median 4.1 μg/mL (IQR 3.4–6.3)
(Table 2), which was significantly higher than in the oli-
goarticular persistent (p = 0.024), polyarticular RF-neg
(p = 0.048), ERA (p = 0.02) and the undifferentiated cat-
egory (p = 0.014). Conversely, MASP-1 levels at baseline
were significantly lower for the systemic group (median
7.4 μg/mL (IQR (4.8–12.1)) compared to oligoarticular
persistent (p = 0.03) and the undifferentiated category
(p = 0.019). The other lectins did not differentiate signifi-
cantly between the groups.
Correlation between markers of disease activity,
treatment, disease status and lectin pathway protein
levels
The protein levels at baseline were compared to ESR,
JADAS71 or cumulative joint count at baseline. M-fico-
lin was positively correlated to the ESR levels (Table 3);
however, the correlation found was weak. At baseline, el-
evated ESR (> 20mm/hr) was observed in 55/238
(23.1%) of patients investigated for lectin pathway
Table 2 Lectin protein concentrations according to JIA subtype early in disease course and at 17-year follow-up
n MBL H-ficolin M-ficolin CL-K1 MASP-1 MASP-3
Baseline
Total cohort 238 3.1(1.2–4.7) 26.3(21.5–29.9) 3.0(2.4–3.9) 0.28(0.23–0.34) 9.9(7.4–13.2) 8.1(6.7–9.3)
sJIA 11 3.8(0.8–4.7) 27.2(20.4–29.6) 4.1(3.4–6.3) 0.31(0.21–0.37) 7.4(4.8–12.1) 8.5(5.7–10.7)
Oligo persist 113 3.3(1.9–4.5) 25.8(21.8–29.9) 3.0(2.4–3.8) 0.28(0.23–0.34) 10.3(7.9–13.3) 8.1(7.2–9.6)
Oligo ext 8 3.1(1.2–4.4) 26.2(21.6–32.3) 3.5(2.3–4.8) 0.30(0.24–0.42) 7.0(5.7–11.5) 8.1(6.2–8.5)
Poly RF- 47 4.4(2.4–6.3) 26.7(21.2–35.3) 3.1(2.4–4.3) 0.28(0.23–0.33) 9.0(6.9–11.7) 7.7(6.4–9.0)
Poly RF+ 5 2.3(2.3–4.6) 24.0(18.4–26.3) 2.8(2.4–2.8) 0.25(0.24–0.35) 8.8(8.5–10.7) 10.0(7.8–10.4)
Psoriatic 2 2.5(2.3–2.8) 24.5(20.4–28.6) 3.3(2.7–3.8) 0.23(0.19–0.26) 15.0(14.9–15.0) 8.2(5.6–10.9)
ERA 20 1.9(0.5–2.8) 26.4(21.9–29.4) 2.9(2.1–3.5) 0.26(0.20–0.33) 10.2(7.0–14.4) 8.1(6.5–9.0)
Undiff 32 2.2(0.5–4.7) 27.0(21.2–29.5) 3.0(2.6–3.5) 0.29(0.26–0.35) 10.6(8.5–3.6) 8.1(7.1–9.0)
17-year follow-up
Total cohort 293 2.0(0.7–3.5) 22.5(18.9–26.1) 2.1(1.7–3.0) 0.24(0.21–0.28) 8.8(6.5–11.3) 6.7(5.6–8.4)
sJIA 13 3.3(1.6–3.8) 21.8(18.0–24.6) 2.2(1.6–2.4) 0.23(0.21–0.25) 8.2(7.7–10.5) 6.4(5.9–6.9)
Oligo persist 66 2.2(0.8–3.3) 22.1(18.8–25.6) 2.3(1.7–3.0) 0.24(0.21–0.27) 9.0(6.8–11.5) 6.6(5.1–8.6)
Oligo ext 55 2.0(0.6–3.3) 21.1(18.5–24.0) 2.0(1.7–2.7) 0.24(0.21–0.28) 9.5(7.5–13.0) 6.7(5.7–8.5)
Poly RF- 53 2.6(1.2–3.8) 22.3(18.8–25.4) 2.1(1.7–2.7) 0.24(0.22–0.28) 9.8(7.5–9.9) 6.7(5.7–8.4)
Poly RF+ 5 1.3(0.0–2.2) 31.4(25.1–36.1) 2.1(1.8–3.3) 0.25(0.23–0.34) 8.4(6.3–10.9) 8.7(7.5–8.8)
Psoriatic 19 2.0(0.7–4.3) 24.9(21.8–30.3) 2.2(1.8–3.1) 0.27(0.22–0.28) 8.7(5.6–12.1) 6.6(5.7–9.1)
ERA 33 1.4(0.6–2.0) 25.4(22.1–30.6) 1.9(1.6–2.6) 0.24(0.20–0.27) 8.1(6.3–10.5) 7.2(5.7–8.9)
Undiff 49 1.9(0.6–3.6) 20.8(17.2–25.8) 2.4(1.9–3.3) 0.24(0.21–0.27) 8.6(6.4–11.7) 6.4(5.3–7.8)
Serum values are medians in μg/mL with 1st-3rd interquartile range (IQR). MBL mannan binding lectin, MASP MBL-associated serine proteases, CL-K1 collectin
kidney, sJIA systemic JIA, Oligo persist oligo persistent JIA, Oligo ext. oligo extended JIA, Poly RF- polyarticular rheumatoid factor negative JIA, Poly RF+ polyarticular
rheumatoid factor positive JIA, ERA enthesitis-related arthritis, Undiff undifferentiated JIA
Glerup et al. Pediatric Rheumatology           (2019) 17:63 Page 4 of 9
proteins. Participants with elevated ESR had significantly
higher M-ficolin levels than those with normal values (me-
dian 3.43 μg/mL (IQR 2.86–4.46) versus median 2.85 μg/
mL (IQR 2.35–3.59) (p < 0.001)). Conversely, for MASP-1
and MASP-3 there was a tendency towards higher levels
in patients with normal ESR compared to elevated ESR
but the difference did not reach significance (p = 0.12 and
p = 0.08, respectively) (data not shown).
CL-K1 showed a weak negative correlation to
JADAS71 at baseline (Table 3). In patients with inactive
disease (JADAS71 ≤ 1) at 17 years of follow-up the serum
M-ficolin levels were significantly lower than in patients
Fig. 2 Differences in lectin pathway protein levels at baseline and 17 years of follow-up. MBL =mannan-binding lectin; MASP =MBL-associated
serine proteases; CL-K1 = collectin kidney1. * p < 0.001; ** p = 0.001
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with active disease (p = 0.026). In addition, MASP-3 cor-
related weakly to the cumulative joint count during the
first 6 months after onset (Table 3).
Comparison of lectin levels 17 years after disease onset
of patients in remission (on or off medication) according
to the preliminary Wallace criteria versus not being in
remission revealed no difference for any of the proteins
(p = 0.10–0.78, n = 293) (data not shown).
None of the six proteins had significant explanatory
power to predict remission off medication in the univari-
ate regression analyses (Table 4). Likewise, the protein
levels at baseline could not predict inactive disease 17
years after disease onset in a multivariate regression ana-
lysis (data not shown).
Discussion
This is the first study to report lectin pathway protein
levels related to JIA disease activity in a long-term follow
up study of participants from the Nordic JIA cohort.
The highest level of M-ficolin at baseline was observed
in systemic JIA which was significantly higher than most
of the other categories. Conversely, MASP-1 levels were
significantly lower for the sJIA compared to the oligoar-
ticular persistent group. We found that a high M-ficolin
level at baseline and 17-year follow-up was correlated to
high ESR and conversely, high MASP-1 and MASP-3
tended to correlate to low ESR. We found a tendency
that high MASP-1 and MASP-3 were associated with
low disease activity and CL-K1 was negatively correlated
to JADAS71 at baseline. Accordingly, we hypothesize
that the high levels of M-ficolin and low levels of
MASP-1 and MASP-3 may reflect inflammation in JIA.
M-ficolin has previously been suggested to be in-
volved in the pathogenesis of rheumatoid arthritis
(RA) with the finding of a 30-fold increase in synovial
fluid levels from patients with active RA compared to
the concentrations in osteoarthritis [4]. M-ficolin is a
protein found in the granules of monocytes and neu-
trophil granulocytes and may be released upon stimu-
lation of the phagocytes [16]. Polymorphisms in the
FCN1 gene coding for M-ficolin have been described
to be associated with the susceptibility to develop
rheumatoid arthritis [36].
In DMARD-naïve patients with early rheumatoid arth-
ritis (RA), increased circulating M-ficolin levels have
been associated with higher disease activity, notably
reflected by DAS28 and the HAQ, at both baseline and
at 1 year [5]. Further, it was demonstrated that M-ficolin
levels at baseline were the strongest predictor of remis-
sion and that baseline M-ficolin in the lowest quartile
indicated a 95% chance of achieving low disease activity
1 year after diagnosis [5].
However, in the present study none of the baseline
levels of lectin pathway proteins were able to predict dis-
ease outcome such as remission status 17 years after dis-
ease onset as otherwise suggested in previous studies in
RA and JIA [5, 8].
Table 3 Correlation between disease activity and lectin levels at baseline and 17-years of follow-up
BASELINE#(n = 238) 17-YEAR FOLLOW-UP (n = 293)
ESR JADAS71 Cum joints ESR JADAS71 Cum joints
MBL N.S. N.S. N.S. N.S. N.S. N.S.
H-ficolin N.S. N.S. N.S. N.S. N.S. N.S.
M-ficolin r = 0.23
p < 0.01
N.S. N.S. r = 0.20
p < 0.01
N.S. N.S.
CL-K1 N.S. r = −0.16
p = 0.05
N.S. r = −0.13
p = 0.05
N.S. N.S.
MASP-1 N.S. N.S. N.S. N.S. N.S. N.S.
MASP3 N.S. N.S. r = −0.13 p = 0.04 N.S. N.S. N.S.
Only results with a p ≤ 0.05 are listed. N.S non-significant. #: Baseline was 6 months (−1/+ 2 months) after disease onset. ESR erythrocytes sedimentation rate at
baseline, JADAS71 juvenile arthritis disease activity score of 71 joints cum joints cumulative joint count, MASP MBL-associated serine proteases, MBL mannan-
binding lectin, CL-K1 collectin kidney, r Spearman’s rho
Table 4 Associations between lectin pathway proteins at
baseline and remission 17 years after disease onset* (n = 238)
Univariate crude odds ratio
(95% CI)
P values
PREDICTORS EARLY IN DISEASE COURSE
ESR 0.984(0.97–0.99) 0.01**
JADAS71 0.91(0.84–0.98) < 0.01**
Cumulative joint count 0.92 (0.88–0.97) < 0.01**
H-ficolin 0.86(0.38–2.25) 0.86
M-ficolin 1.53(0.69–3.42) 0.30
MASP-1 1.14(0.58–2.28) 0.70
MASP-3 0.87(0.26–2.93) 0.82
MBL 1.06(0.87–1.29) 0.56
CL-K1 1.69(0.62–4.60) 0.31
*according to the preliminary Wallace criteria, ESR erythrocytes sedimentation
rate at baseline, JADAS27 juvenile arthritis disease activity score of 27 joints;
cumulative joint count cumulative joint count within the first 6 months (−1/+ 2
months) after disease onset, MASP MBL-associated serine proteases, MBL
mannan-binding lectin, CL-K1 collectin kidney 1, ** Statistical
significance (p ≤ 0.05)
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An advancement of studies on the lectin pathway be-
ing a part of the pathogenesis in autoimmune diseases
[6, 37], including JIA, could potentially lead to the iden-
tification of novel biomarkers. These biomarkers are of
particular interest as they reflect more disease-specific
information than the nonspecific acute-phase reactants
available today (C-reactive protein (CRP) and erythro-
cyte sedimentation rate (ESR)). Understanding the mo-
lecular source for the JIA disease heterogeneity of JIA
will be a milestone in identifying biomarkers of inflam-
mation; markers that may prove valuable in therapeutic
patient stratification and prediction of future disease be-
havior early in the disease course. Our findings suggest
that increased circulating M-ficolin levels are associated
with higher disease activity and presumably reflect bio-
markers of inflammation in JIA. The lower levels of
MASP-1 and MASP-3 when inflammatory activity is
high may be suggestive of a consumption of activated
enzymes, e.g. as a result of binding of the serpin C1-in-
hibitor to MASP-1 [38].
Consistent with our findings, Petri et al. [24] reported
that M-ficolin levels were higher in patients with sJIA
than oligo persistent JIA in a study of 128 children
within the first year of disease course. Our data support
the idea that innate immune mechanisms play an im-
portant role in sJIA [39, 40] and thus differs in its biol-
ogy compared to the non-systemic JIA categories.
Kasperkiewicz et al. [11] found no difference between
M-ficolin levels in the oligo- and polyarticular groups
which also is coherent with the findings in our cohort.
A positive correlation between markers of disease ac-
tivity and M-ficolin in JIA has also been demonstrated
previously [24], and we can now add CL-K1 as another
protein that correlates to disease activity. To our know-
ledge this is the first study to investigate this protein in
JIA. Inversely, higher levels of MASP-1 and MASP-3
were found in the oligo persistent category compared to
the sJIA category which is consistent with the findings
of Petri et al. [24].
There have been several studies on the association of
MBL deficiency and the susceptibility to JIA but the con-
clusions are contradictive [8, 11, 22, 41]. In 2017, Kasper-
kiewcz et al. [11] found no difference between MBL levels
in the oligo- and polyarticular categories which is consist-
ent with our results. The median MBL levels were lower
compared to our findings, but no further interpretation
can be made as they used a different method, and no clin-
ical data on the disease duration, disease activity or treat-
ment were provided. We found no correlation between
MBL and disease activity markers suggesting that our
findings cannot support the idea that MBL play a major
role in the pathogenesis of JIA.
The population-based setting and the prospective de-
sign with paired follow-up samples closely related to
measurements of disease activity are strengths of the
present study.
A limitation of the study is the number of patients lost
to follow-up and the small sample size in some of the
JIA categories. Although being a small group the in-
cluded 4.4% representing the sJIA category were com-
parable to the sJIA representation in other Nothern
European, Western European and North American co-
horts [42]. A concern could be the long-term stability of
complement proteins over such a long storage period.
Although we know storage for 5 years will have no influ-
ence on the measured levels (as indicated be the stability
of the internal controls we keep in the freezer) the very
long-term stability of the proteins is not fully elucidated
and might have affected the results. Normal values for
healthy children have not been studied previously; how-
ever, our baseline values are comparable to the levels
found by Petri et al. [24]. We found no differences in
age at onset or JIA categories between the participants
and those lost to follow-up, but more girls and a higher
number of active joints at baseline in the included
group. The latter might have skewed the baseline levels
of the proteins that are correlated to disease activity to-
wards even higher levels. Further, the baseline samples
were collected 6 months after disease onset, and almost
19% of the patients were on disease-modifying anti-
rheumatic drugs when the samples were taken, which
may have influenced the protein levels and conceivably
have impaired the predictive abilities of the lectin pro-
tein as seen in RA studies [5].
Conclusions
In summary, this study contributes with novel insights
into the possible role of the lectin pathway in driving the
ongoing inflammation in JIA although the exact mech-
anism is not completely understood. The results sub-
stantiate that M-ficolin is a marker of disease activity
and additionally, MASP-1, MASP-3 and CL-K1 show
weak correlations to changes in disease activity.; how-
ever, the levels of lectin pathway proteins measured early
after disease onset could not anticipate the future disease
course. Further studies in treatment naïve cohorts are
needed to achieve a better understanding of the disease
pathogenesis of JIA.
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